The role of mitogen activated protein kinase signaling in microglia and neurons in the initiation and maintenance of chronic pain

Experimental Neurology

Volumn 234, Issue 2, 2012, Pages 330-339

  Crown, Eric D ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; D STRESS ACTIVATED PROTEIN KINASE INHIBITOR 1; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PD 198306; SB 600125; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTHRALGIA; CELL ACTIVATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHRONIC PAIN; DIABETIC NEUROPATHY; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; MICROGLIA; NERVE CELL; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SCIATIC NERVE; TREATMENT RESPONSE;

ANIMALS; CHRONIC PAIN; DIABETIC NEUROPATHIES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; NEURONS; OSTEOARTHRITIS;

EID: 84858152891     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.10.019     Document Type: Review

References (91)

1. Abramson S.B., Attur M. Developments in the scientific understanding of osteoarthritis. Arthritis Res. Ther. 2009, 11:227.
2. Ahlgren S.C., Levine J.D. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 1993, 52:1049-1055.
3. Allen A.R. Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column. A preliminary report. JAMA 1911, 57:878-880.
4. Anand P., Shenoy R., Palmer J.E., Baines A.J., Lai R.Y., Robertson J., Bird N., Ostenfeld T., Chizh B.A. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur. J. Pain 2011, (epub April 5).
5. Badrinarayan P., Sastry G.N. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads. J. Chem. Inf. Model. 2011, 51:115-129.
6. Basso D.M., Beattie M.S., Bresnahan J.C. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp. Neurol. 1996, 139:244-256.
7. Bendele A.M. Animal models of osteoarthritis. J. Musculoskelet. Neuronal. Interact. 2001, 1:363-376.
8. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
9. Beyreuther B., Callizot N., Stohr T. Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain. Arthritis Res. Ther. 2007, 9:R14.
10. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.M., Guzman R.E., Juneau P.L., Schrier D.J., Kilgore K.S. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthr. Cartil. 2003, 11:821-830.
11. Bruce J.C., Oatway M.A., Weaver L.C. Chronic pain after clip-compression injury of the rat spinal cord. Exp. Neurol. 2002, 178:33-48.
12. Chandran P., Pai M., Blomme E.A., Hsieh G.C., Decker M.W., Honore P. Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis. Eur. J. Pharmacol. 2009, 613:39-45.
13. Christensen M.D., Everhart A.W., Pickelman J.T., Hulsebosch C.E. Mechanical and thermal allodynia in chronic central pain following spinal cord injury. Pain 1996, 68:97-107.
14. Ciruela A., Dixon A.K., Bramwell S., Gonzalez M.I., Pinnock R.D., Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br. J. Pharmacol. 2003, 138:751-756.
15. Clancy R., Rediske J., Koehne C., Stoyanovsky D., Amin A., Attur M., Iyama K., Abramson S.B. Activation of stress-activated protein kinase in osteoarthritic cartilage: evidence for nitric oxide dependence. Osteoarthr. Cartil. 2001, 9:294-299.
16. Clutterbuck A.L., Asplin K.E., Harris P., Allaway D., Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr. Drug Targets 2009, 10:1245-1254.
17. Courteix C., Eschalier A., Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993, 53:81-88.
18. Crown E.D., Ye Z., Johnson K.M., Xu G.Y., McAdoo D.J., Westlund K.N., Hulsebosch C.E. Upregulation of the phosphorylated form of CREB in spinothalamic tract cells following spinal cord injury: relation to central neuropathic pain. Neurosci. Lett. 2005, 384:139-144.
19. Crown E.D., Ye Z., Johnson K.M., Xu G.Y., McAdoo D.J., Hulsebosch C.E. Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-level mechanical allodynia following spinal cord injury. Exp. Neurol. 2006, 199:397-407.
20. Crown E.D., Gwak Y.S., Ye Z., Johnson K.M., Hulsebosch C.E. Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injury. Exp. Neurol. 2008, 213:257-267.
21. Daulhac L., Mallet C., Courteix C., Etienne M., Duroux E., Privat A.M., Eschalier A., Fialip J. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol. Pharmacol. 2006, 70:1246-1254.
22. Decosterd I., Woolf C.J. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000, 87:149-158.
23. Detloff M.R., Fisher L.C., McGaughy V., Longbrake E.E, Popovich P.G., Basso D.M. Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Exp. Neurol. 2008, 212:337-347.
24. Di Cesare Mannelli L., Ghelardini C., Toscano A., Pacini A., Bartolini A. The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 2010, 165(4):1345-1352.
25. Fan Z., Soder S., Oehler S., Fundel K., Aigner T. Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am. J. Pathol. 2007, 171:938-946.
26. Ferland C.E., Laverty S., Beaudry F., Vachon P. Gait analysis and pain response of two rodent models of osteoarthritis. Pharmacol. Biochem. Behav. 2011, 97:603-610.
27. Fernihough J., Gentry C., Malcangio M., Fox A., Rediske J., Pellas T., Kidd B., Bevan S., Winter J. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 2004, 112:83-93.
28. Gao Y.J., Ji R.R. Targeting astrocyte signaling for chronic pain. Neurotherapeutics 2010, 7:482-493.
29. Garuti L., Roberti M., Bottegoni G. Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem. 2010, 17:2804-2821.
30. Guingamp C., Gegout-Pottie P., Philippe L., Terlain B., Netter P., Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997, 40:1670-1679.
31. Gwak Y.S., Hulsebosch C.E. Remote astrocytic and microglial activation modulates neuronal hyperexcitability and below-level neuropathic pain after spinal injury in rat. Neuroscience 2009, 161:895-903.
32. Gwak Y.S., Nam T.S., Paik K.S., Hulsebosch C.E., Leem J.W. Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neurosci. Lett. 2003, 336:117-120.
33. Gwak Y.S., Crown E.D., Unabia G.C., Hulsebosch C.E. Propentofylline attenuates allodynia, glial activation and modulates GABAergic tone after spinal cord injury in the rat. Pain 2008, 138:410-422.
34. Gwak Y.S., Unabia G.C., Hulsebosch C.E. Activation of p-38alpha MAPK contributes to neuronal hyperexcitability in caudal regions remote from spinal cord injury. Exp. Neurol. 2009, 220:154-161.
35. Hains B.C., Waxman S.G. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J. Neurosci. 2006, 26:4308-4317.
36. Hao J.X., Xu X.J., Aldskogius H., Seiger A., Wiesenfeld-Hallin Z. Photochemically induced transient spinal ischemia induces behavioral hypersensitivity to mechanical and cold stimuli, but not to noxious-heat stimuli, in the rat. Exp. Neurol. 1992, 118:187-194.
37. Harvey V.L., Dickenson A.H. Behavioural and electrophysiological characterisation of experimentally induced osteoarthritis and neuropathy in C57Bl/6 mice. Mol. Pain 2009, 5:18.
38. Heitmeyer S.A., Brown K.K., Hookfin E.B., Buchalova M., Fei L., Fryer D.A. Orally dosed p38 inhibitors reduce cartilage damage in the rat iodoacetate model of osteoarthritis. 50th Annual Meeting of the Orthopaedic Research Society, Poster No. 0930 2004.
39. Hulsebosch C.E., Xu G.Y., Perez-Polo J.R., Westlund K.N., Taylor C.P., McAdoo D.J. Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. J. Neurotrauma 2000, 17:1205-1217.
40. Hulsebosch C.E., Hains B.C., Crown E.D., Carlton S.M. Mechanisms of chronic central neuropathic pain after spinal cord injury. Brain Res. Rev. 2009, 60:202-213.
41. Institute of Medicine of the National Academies Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research (Accessed June 29). http://www.iom.edu/~/media/Files/Report%20Files/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research/Pain%20Research%202011%20Report%20Brief.pdf.
42. Jaggi A.S., Singh N. Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain. CNS Neurol Disord Drug Targets 2011, (epub Jun 1).
43. Ji R.R. Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases. Curr. Drug Targets Inflamm. Allergy 2004, 3:299-303.
44. Ji R.R., Strichartz G. Cell signaling and the genesis of neuropathic pain. Sci. STKE 2004, (reE14).
45. Ji R.R., Woolf C.J. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol. Dis. 2001, 8:1-10.
46. Ji R.R., Kohno T., Moore K.A., Woolf C.J. Central sensitization and LTP: do pain and memory share similar mechanisms?. Trends Neurosci. 2003, 26:696-705.
47. Ji R.R., Kawasaki Y., Zhuang Z.Y., Wen Y.R., Decosterd I. Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol. 2006, 2:259-269.
48. Ji R.R., Kawasaki Y., Zhuang Z.Y., Wen Y.R., Zhang Y.Q. Protein kinases as potential targets for the treatment of pathological pain. Handb. Exp. Pharmacol. 2007, 359-389.
49. Ji R.R., Gereau R.W., Malcangio M., Strichartz G.R. MAP kinase and pain. Brain Res. Rev. 2009, 60:135-148.
50. Jin S.X., Zhuang Z.Y., Woolf C.J., Ji R.R. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci. 2003, 23:4017-4022.
51. Johnson G.L., Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim. Biophys. Acta 2007, 1773:1341-1348.
52. Kim S.H., Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50:355-363.
53. Kim S.Y., Bae J.C., Kim J.Y., Lee H.L., Lee K.M., Kim D.S., Cho H.J. Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport 2002, 13:2483-2486.
54. Kim J., Yoon Y.W., Hong S.K., Na H.S. Cold and mechanical allodynia in both hindpaws and tail following thoracic spinal cord hemisection in rats: time courses and their correlates. Neurosci. Lett. 2003, 343:200-204.
55. Krzeski P., Buckland-Wright C., Balint G., Cline G.A., Stoner K., Lyon R., Beary J., Aronstein W.S., Spector T.D. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res. Ther. 2007, 9:R109.
56. Kumar S., Boehm J., Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2003, 2:717-726.
57. Kupers R., Yu W., Persson J.K., Xu X.J., Wiesenfeld-Hallin Z. Photochemically-induced ischemia of the rat sciatic nerve produces a dose-dependent and highly reproducible mechanical, heat and cold allodynia, and signs of spontaneous pain. Pain 1998, 76:45-59.
58. LaBuda C.J., Little P.J. Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat. J. Neurosci. Methods 2005, 144:175-181.
59. Lee Y., Pai M., Brederson J.D., Wilcox D., Hsieh G., Jarvis M.F., Bitner R.S. Monosodium iodoacetate-induced joint pain is associated with increased phosphorylation of mitogen activated protein kinases in the rat spinal cord. Mol. Pain 2011, 7:39.
60. Liu Y.L., Zhou L.J., Hu N.W., Xu J.T., Wu C.Y., Zhang T., Li Y.Y., Liu X.G. Tumor necrosis factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPK. Neuropharmacology 2007, 52:708-715.
61. Loeser R.F. Molecular mechanisms of cartilage destruction in osteoarthritis. J. Musculoskelet. Neuronal. Interact. 2008, 8:303-306.
62. Loeser R.F., Erickson E.A., Long D.L. Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr. Opin. Rheumatol. 2008, 20:581-586.
63. Ma W., Quirion R. Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain 2002, 99:175-184.
64. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
65. McDevitt C., Gilbertson E., Muir H. An experimental model of osteoarthritis; early morphological and biochemical changes. J. Bone Joint Surg. Br. 1977, 59:24-35.
66. Obata K., Yamanaka H., Dai Y., Mizushima T., Fukuoka T., Tokunaga A., Noguchi K. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur. J. Neurosci. 2004, 20:2881-2895.
67. Peng X.M., Zhou Z.G., Glorioso J.C., Fink D.J., Mata M. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann. Neurol. 2006, 59:843-851.
68. Read S.J., Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opin. Investig. Drugs 2008, 17:619-640.
69. Romanovsky D., Walker J.C., Dobretsov M. Pressure pain precedes development of type 2 disease in Zucker rat model of diabetes. Neurosci. Lett. 2008, 445:220-223.
70. Seino D., Tokunaga A., Tachibana T., Yoshiya S., Dai Y., Obata K., Yamanaka H., Kobayashi K., Noguchi K. The role of ERK signaling and the P2X receptor on mechanical pain evoked by movement of inflamed knee joint. Pain 2006, 123:193-203.
71. Seltzer Z., Dubner R., Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990, 43:205-218.
72. Siddall P., Xu C.L., Cousins M. Allodynia following traumatic spinal cord injury in the rat. Neuroreport 1995, 6:1241-1244.
73. Siddall P.J., Taylor D.A., McClelland J.M., Rutkowski S.B., Cousins M.J. Pain report and the relationship of pain to physical factors in the first 6 months following spinal cord injury. Pain 1999, 81:187-197.
74. Smyth L.A., Collins I. Measuring and interpreting the selectivity of protein kinase inhibitors. J. Chem. Biol. 2009, 2:131-151.
75. Sweitzer S.M., Medicherla S., Almirez R., Dugar S., Chakravarty S., Shumilla J.A., Yeomans D.C., Protter A.A. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 2004, 109:409-419.
76. Tu G., Xu W., Huang H., Li S. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2008, 15:1388-1395.
77. Ueta K., Ishihara T., Matsumoto Y., Oku A., Nawano M., Fujita T., Saito A., Arakawa K. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci. 2005, 76:2655-2668.
78. Vulpetti A., Bosotti R. Sequence and structural analysis of kinase ATP pocket residues. Farmaco 2004, 59:759-765.
79. Wall P.D., Devor M., Inbal R., Scadding J.W., Schonfeld D., Seltzer Z., Tomkiewicz M.M. Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain 1979, 7:103-111.
80. Wang H., Dai Y., Fukuoka T., Yamanaka H., Obata K., Tokunaga A., Noguchi K. Enhancement of stimulation-induced ERK activation in the spinal dorsal horn and gracile nucleus neurons in rats with peripheral nerve injury. Eur. J. Neurosci. 2004, 19(4):884-890.
81. Wei T., Kulkarni N.H., Zeng Q.Q., Helvering L.M., Lin X., Lawrence F., Hale L., Chambers M.G., Lin C., Harvey A., Ma Y.L., Cain R.L., Oskins J., Carozza M.A., Edmondson D.D., Hu T., Miles R.R., Ryan T.P., Onyia J.E., Mitchell P.G. Analysis of early changes in the articular cartilage transcriptisome in the rat meniscal tear model of osteoarthritis: pathway comparisons with the rat anterior cruciate transection model and with human osteoarthritic cartilage. Osteoarthr. Cartil. 2010, 18:992-1000.
82. Wen Y.R., Suter M.R., Kawasaki Y., Huang J., Pertin M., Kohno T., Berde C.B., Decosterd I., Ji R.R. Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model. Anesthesiology 2007, 107:312-321.
83. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79:143-180.
84. Woolf C.J., Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 2000, 288:1765-1769.
85. Xu X.J., Hao J.X., Aldskogius H., Seiger A., Wiesenfeld-Hallin Z. Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury. Pain 1992, 48:279-290.
86. Yezierski R.P., Park S.H. The mechanosensitivity of spinal sensory neurons following intraspinal injections of quisqualic acid in the rat. Neurosci. Lett. 1993, 157:115-119.
87. Yezierski R.P., Santana M., Park S.H., Madsen P.W. Neuronal degeneration and spinal cavitation following intraspinal injections of quisqualic acid in the rat. J. Neurotrauma 1993, 10:445-456.
88. Yu C.G., Yezierski R.P. Activation of the ERK1/2 signaling cascade by excitotoxic spinal cord injury. Brain Res. Mol. Brain Res. 2005, 138:244-255.
89. Zhao P., Waxman S.G., Hains B.C. Modulation of thalamic nociceptive processing after spinal cord injury through remote activation of thalamic microglia by cysteine cysteine chemokine ligand 21. J. Neurosci. 2007, 27:8893-8902.
90. Zhuang Z.Y., Gerner P., Woolf C.J., Ji R.R. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114:149-159.
91. Zhuang Z.Y., Wen Y.R., Zhang D.R., Borsello T., Bonny C., Strichartz G.R., Decosterd I., Ji R.R. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J. Neurosci. 2006, 26:3551-3560.